article thumbnail

Investors put $400M into biotech licensing obesity drugs from China

BioPharma Drive: Drug Pricing

The biotech, tentatively named Hercules CM Newco, has rights to three incretin drugs discovered by Jiangsu Hengrui Pharmaceuticals, two of which are in clinical testing.

Licensing 356
article thumbnail

How to Identify Branded Drugs with a Low Likelihood of Generic Entry as Targets for In-Licensing

Drug Patent Watch

Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. In this comprehensive guide, we’ll explore the intricacies of identifying such drugs and leveraging them for successful in-licensing opportunities.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Roche licenses Sangamo’s technology for another shot at Alzheimer’s drugs

BioPharma Drive: Drug Pricing

Through a new deal, Roche has exclusive rights to Sangamo molecules designed to repress the gene that makes “tau,” a protein many scientists view as a main driver of Alzheimer’s.

Licensing 332
article thumbnail

Reproductive health startup raises $65M for infertility drugs

BioPharma Drive: Drug Pricing

Founded in 2021, ReproNovo has licensed rights to two drugs from Mereo BioPharma and ObsEva that it thinks could address fertility issues in men and women.

Licensing 144
article thumbnail

Biogen strikes RNAi deal with City; Aurion withdraws IPO

BioPharma Drive: Drug Pricing

Elsewhere, Angelini Pharma licensed a rare disease therapy and the FDA refused to review a Savara lung drug. City will receive $46 million from Biogen under the alliance.

Licensing 185
article thumbnail

Takeda pays $300M to license Protagonist drug for blood disorder

BioPharma Drive: Drug Pricing

The agreement gives Protagonist an experienced hand in Takeda, which can help the former commercialize its product.

Licensing 284
article thumbnail

GSK to pay $300M to license drug it sees as potential lupus treatment

BioPharma Drive: Drug Pricing

The licensing deal with China’s Chimagen Biosciences is the latest example of drugmaker interest in exploring the potential of “T cell engagers” in autoimmune disease.

Licensing 176